Compare U & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | U | HALO |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0B | 7.4B |
| IPO Year | 2020 | N/A |
| Metric | U | HALO |
|---|---|---|
| Price | $45.81 | $68.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 12 |
| Target Price | $39.84 | ★ $73.33 |
| AVG Volume (30 Days) | ★ 7.2M | 2.3M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.68 |
| EPS | N/A | ★ 4.74 |
| Revenue | ★ $1,803,658,000.00 | $1,242,852,000.00 |
| Revenue This Year | $3.13 | $34.83 |
| Revenue Next Year | $12.89 | $24.84 |
| P/E Ratio | ★ N/A | $14.44 |
| Revenue Growth | N/A | ★ 31.19 |
| 52 Week Low | $15.33 | $46.76 |
| 52 Week High | $52.15 | $79.50 |
| Indicator | U | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 57.58 |
| Support Level | $44.06 | $61.23 |
| Resistance Level | $47.77 | $69.28 |
| Average True Range (ATR) | 2.18 | 1.72 |
| MACD | -0.34 | 0.66 |
| Stochastic Oscillator | 21.24 | 89.20 |
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. The products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.